Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
NCT ID: NCT06919328
Last Updated: 2025-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
70 participants
INTERVENTIONAL
2024-10-31
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
IV Administration of ChromaDex's Niagen® as Compared to NAD+
NCT06382688
Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)
NCT06005350
A Study Investigating the Effects of Niagen™ in Healthy Adults.
NCT02712593
Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults
NCT02921659
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
NCT06882096
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NR via IM injection
100mg NR 2ml bacteriostatic water via intramuscular (IM) injection
Niagen®
nicotinamide riboside
NR via subcutaneous injection
100mg NR 2ml bacteriostatic water via subcutaneous (SQ) injection
Niagen®
nicotinamide riboside
NR via IV push
100mg NAD+ 2ml bacteriostatic water via intravenous push (IVP) injection
Niagen®
nicotinamide riboside
NAD+ via IM injection
100mg NAD+ in 2ml bacteriostatic water via intramuscular (IM) injection
NAD+
Nicotinamide adenine dinucleotide
NAD+ via subcutaneous injection
100mg NAD+ in 2ml bacteriostatic water via subcutaneous (SQ) injection
NAD+
Nicotinamide adenine dinucleotide
NAD+ via IV push
100mg NAD+ 2ml bacteriostatic water via intravenous push (IVP) injection
NAD+
Nicotinamide adenine dinucleotide
placebo via IM injection
2ml bacteriostatic water via intramuscular (IM) injection
Placebo
bacteriostatic water
placebo via subcutaneous injection
2ml bacteriostatic water via subcutaneous (SQ) injection
Placebo
bacteriostatic water
placebo via IV push
2ml bacteriostatic water via intravenous push (IVP) injection
Placebo
bacteriostatic water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Niagen®
nicotinamide riboside
NAD+
Nicotinamide adenine dinucleotide
Placebo
bacteriostatic water
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study
* Lives within 100 miles of the NRI study site
* Any gender, aged 40-65, inclusive
* Good general health as evidenced by medical history
* BMI 25-34.9 kg/m2
* Sedentary behavior (defined as \<20 minutes per day or 100 minutes per week of moderate to vigorous exercise)
* Demonstrated fatigue (Fatigue Assessment Scale) defined as a below-average score
* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional month after the end of the study
* Agreement to adhere to Lifestyle Considerations throughout study duration
Exclusion Criteria
* ANY chronic illness (pre-disease state acceptable)
* Out of range phosphate levels at baseline
* BMI less than 25 or greater than or equal to 35
* Pregnancy, trying to conceive, or breastfeeding
* Known allergic reactions to any components of the intervention or related compounds, including any form of B3
* Positive COVID-19 test within 30 days of the study period
* Recent dramatic weight changes (10% change in body weight in the last 6 months)
* Existing usage of a NAD+ or NAD precursor supplement in any form (oral, nasal, patch, or injection/IV administration), including a B-complex supplement, within 60 days of the study, not including multivitamins.
* Introducing a new medication, supplement, investigational drug, or other intervention (including lifestyle changes) within 60 days of the start of the study.
40 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ChromaDex, Inc.
INDUSTRY
Nutraceuticals Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jessie Hawkins
PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nutraceuticals Research Institute
Huntsville, Alabama, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24-09-1300
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.